Key result
Anti-apoptotic interventions show potential in HF by targeting programmed cell death pathways.
Why the study?
Apoptosis plays a key role in cardiovascular diseases including myocardial infarction, reperfusion injury, and heart failure, but anti-apoptotic interventions at the chronic stage of heart failure are limited.
Anti-apoptotic strategies remain largely untested in chronic heart failure; leaves open targeted development for this phase.
Apoptosis or progress of programmed cell death is a tightly regulated process which plays an important role in various cardiovascular diseases particularly in myocardial infarction, reperfusion injury, and heart failure. Over the past two decades, investigations of several pathways have broadened our understanding of programmed cell death. Many anti-apoptotic interventions have targeted ischemia- reperfusion, however only a limited number have been considered at the chronic stage of heart failure. Endogenous inhibitors, caspase inhibitors, PARP-1 inhibitors, as well as various other agents have been implicated as anti-apoptotic interventions. This review summarizes the apoptotic pathways associated with heart failure, discusses the current anti-apoptotic interventions available and reviews the clinical implications.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2011) conducted a review in Cardiovascular diseases (myocardial infarction, reperfusion injury, heart failure). Anti-apoptotic interventions was evaluated. Anti-apoptotic interventions, including caspase and PARP-1 inhibitors, offer potential therapeutic strategies for cardiovascular diseases by targeting programmed cell death pathways in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: